ciltacabtagene autoleucel
| Brand name | Carvykti |
|---|---|
| Active ingredient | ciltacabtagene autoleucel |
| Strength | 0.5 to 1.0x10^6 chimeric antigen receptor (CAR)-positive viable T cells per kg of body weight, with a maximum dose of 1x10^8 CAR-positive viable T cells in one infusion |
| Dosage form | For Injection |
| Route | Intravenous |
| Modality | Biologic |
| FDA approval | February 2022 |
| Marketing status | Rx |
Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the FDA regulatory exclusivity expiry; estimates are projections, not legal advice.